Tom Lowery

Tom Lowery is the Chief Scientific Officer at T2 Biosystems. Tom has been with the company since its inception in February 2007 and has played a pivotal role in its success.

As the first full-time employee, Lowery led early research and built and led the teams that invented and developed T2MR technology. This technology is now used in immunoassays, functional hemostasis assays, and ultra-high sensitivity cell-based molecular diagnostic assays for fungal, bacterial, and antibiotic resistant pathogens.

Lowery has been instrumental in obtaining multiple FDA clearances and CE-marks for the T2MR technology, including the first FDA-cleared direct-from-blood sepsis pathogen panel and the first miniature-NMR-based in vitro diagnostic instrument. Tom has also led and been involved in numerous pilot and pivotal clinical studies that are observational and interventional, single and multi-center, within the US and abroad.

Lowery's work has resulted in "substantial clinical improvements" (according to CMS) for hospitals around the world that are using the T2MR technology. Tom is proud to have been a part of this life-changing technology from the very beginning.

Tom Lowery started their educational career by getting a B.S. in Biochemistry from Brigham Young University. Tom then went on to get a Ph.D. in Chemistry from the University of California, Berkeley, with a focus in Biophysical Chemistry.

Tom Lowery reports to John Sperzel, President and Chief Executive Officer. Tom Lowery works with Alec Barclay - Senior Vice President, Operations, Sandy J. Estrada - Vice President, Medical Affairs, and Kelley Morgan - Vice President, Human Resources.